ADVENTRX Pharmaceuticals Financial Statements
ADVENTRX Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
ADVENTRX Pharmaceuticals Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.5 | 0.0 | 0.5 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (24.3) | (29.8) | (13.2) |
| Total Net Income ($ mil.) | (22.1) | (29.3) | (24.8) |
| Diluted EPS (Net Income) | (0.25) | (0.40) | (0.41) |
ADVENTRX Pharmaceuticals Quarterly Statements
| Quarter Ending Jun 08 | Quarter Ending Mar 08 | Quarter Ending Dec 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.5 | 0.0 | 0.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (6.7) | (6.2) | (5.8) |
| Total Net Income ($ mil.) | (6.4) | (5.9) | (5.4) |
| Diluted EPS (Net Income) | (0.07) | (0.07) | (0.06) |
ADVENTRX Pharmaceuticals Stock Quote & Chart
10/10/08 15:00:06 EST •
AMEX •
0.20
•
 +0.0600
•
+42.8571 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
ADVENTRX Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 37.91 | 2.88 | 1.30 |
| Price/Earnings Ratio | -- | 12.42 | 13.75 |
| Price/Book Ratio | 0.96 | 2.31 | 1.26 |
| Price/Cash Flow Ratio | -- | 11.05 | 8.19 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed ADVENTRX Pharmaceuticals Financial Ratios
ADVENTRX Pharmaceuticals Competitive Intelligence
| GlaxoSmithKline | Roche | Sanofi-Aventis | |
|---|---|---|---|
| Annual Sales ($ mil.) | 22,716.0 | 34,465.2 | 43,019.0 |
| Employees | 103,401 | 74,372 | 99,495 |
| Market Cap ($ mil.) | -- | -- | -- |
Competitive Landscape
